Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)232.57m
- Net income in EUR84.58m
- Incorporated1986
- Employees477.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coor Service Management Holding AB | 1.09bn | 28.40m | 740.00m | 10.41k | 25.90 | 3.76 | 11.13 | 0.6801 | 3.09 | 3.09 | 118.25 | 21.28 | 1.73 | -- | 7.90 | 1,118,015.00 | 4.53 | 2.85 | 7.69 | 4.61 | 11.45 | 10.36 | 2.61 | 1.94 | -- | 9.50 | 0.529 | 179.71 | 5.35 | 6.80 | 38.74 | 16.59 | 0.00 | 5.92 |
| Logwin AG SA | 2.25bn | 75.83m | 749.94m | 4.10k | 9.87 | 2.38 | 6.44 | 0.3334 | 26.34 | 26.34 | 781.43 | 109.31 | 2.98 | 1,714.73 | 8.01 | 550,401.50 | 10.16 | 7.52 | 20.85 | 14.84 | 8.76 | 8.68 | 3.41 | 3.13 | 1.47 | 46.96 | 0.1895 | 27.80 | 64.86 | 13.34 | 82.49 | 19.35 | 14.02 | 24.57 |
| Cary Group Holding AB | 278.65m | 9.80m | 827.27m | 1.54k | 50.45 | 5.06 | 25.90 | 2.97 | 1.29 | 1.29 | 27.66 | 12.83 | 0.6562 | 5.93 | 7.56 | 1,869,405.00 | 2.35 | -- | 2.83 | -- | 65.45 | -- | 3.58 | -- | 1.00 | 2.89 | 0.6577 | -- | 28.94 | -- | -46.54 | -- | -- | -- |
| Marlowe PLC | 374.25m | 829.30k | 858.72m | 5.37k | 781.80 | 1.62 | 24.49 | 2.29 | 0.0097 | 0.0097 | 3.82 | 4.65 | 0.5378 | 28.97 | 5.54 | 58,826.82 | 0.1192 | -0.0482 | 0.1441 | -0.0608 | 44.06 | 41.11 | 0.2216 | -0.0665 | 1.06 | 6.92 | 0.2695 | -- | 64.53 | 46.51 | 141.18 | 18.47 | 86.81 | -- |
| Believe SA | 669.25m | -18.35m | 961.33m | 1.56k | -- | 2.42 | 40.72 | 1.44 | -0.1915 | -0.1915 | 6.99 | 4.13 | 0.7347 | 94.04 | 5.07 | 427,906.00 | -1.67 | -- | -3.31 | -- | 32.98 | -- | -2.27 | -- | 1.10 | -- | 0.0783 | -- | 30.75 | -- | -11.92 | -- | -- | -- |
| Applus Services SA | 1.92bn | 39.30m | 983.25m | 25.76k | 25.02 | 1.55 | 4.31 | 0.512 | 0.2748 | 0.2748 | 13.43 | 4.45 | 0.8342 | 15.74 | 7.66 | 75,973.34 | 2.50 | 0.8705 | 3.35 | 1.12 | 90.59 | 90.48 | 2.99 | 1.09 | 1.21 | 5.65 | 0.6141 | -- | 14.07 | 2.29 | 120.38 | 10.53 | 3.26 | 2.90 |
| iEnergizer Limited | 255.36m | 73.13m | 1.03bn | 1.37k | 14.04 | 17.87 | 12.85 | 4.02 | 0.3246 | 0.3246 | 1.13 | 0.2551 | 1.02 | -- | 6.97 | -- | 29.10 | 19.76 | 37.13 | 25.01 | 83.68 | 79.16 | 28.64 | 22.30 | -- | 11.23 | 0.7275 | 66.70 | 29.93 | 12.05 | 52.32 | 37.88 | 77.06 | -- |
| KRUK S.A. | 405.25m | 172.68m | 1.08bn | 3.27k | 6.41 | 1.77 | 5.91 | 2.67 | 41.48 | 41.48 | 97.30 | 150.65 | 0.3474 | 0.4078 | 94.12 | 581,581.60 | 14.81 | 7.62 | 17.00 | 8.65 | 99.48 | 99.13 | 42.62 | 26.27 | 0.6385 | 10.24 | 0.5034 | 38.26 | 51.93 | 17.19 | 753.97 | 22.81 | 0.9014 | 45.41 |
| Next Fifteen Communications Group plc | 556.88m | -82.00m | 1.10bn | 2.88k | -- | 14.61 | -- | 1.97 | -0.7462 | -0.7462 | 5.09 | 0.6446 | 1.23 | -- | 4.77 | 163,270.20 | -17.14 | -3.15 | -27.77 | -4.70 | 77.03 | 81.11 | -13.97 | -2.73 | -- | 47.92 | 0.4744 | -- | 45.23 | 22.41 | -1,301.76 | -- | -8.20 | 17.98 |
| Volati AB | 701.34m | 35.26m | 1.12bn | 1.97k | 29.07 | 5.72 | 16.91 | 1.60 | 4.60 | 4.60 | 91.43 | 23.36 | 1.22 | 3.75 | 6.11 | 4,213,581.00 | 7.57 | 5.23 | 16.28 | 7.59 | 37.27 | 41.15 | 6.21 | 5.24 | 0.4479 | 16.23 | 0.5916 | 68.61 | 28.21 | 14.49 | 103.49 | 21.52 | 21.65 | 27.73 |
| Pharma Mar SA | 232.57m | 84.58m | 1.14bn | 477.00 | 13.28 | 5.44 | 12.60 | 4.91 | 4.68 | 4.68 | 12.87 | 11.44 | 0.6343 | 1.11 | 7.69 | 487,574.40 | 23.07 | 16.04 | 30.21 | 24.70 | 93.01 | 91.18 | 36.37 | 20.58 | 2.67 | -- | 0.1743 | -- | -14.87 | 4.90 | -32.35 | -- | 5.07 | -- |
| Ascential PLC | 515.23m | -82.57m | 1.30bn | 2.40k | -- | 1.37 | -- | 2.52 | -0.1678 | -0.0893 | 1.04 | 1.81 | 0.3181 | 64.08 | 4.14 | 181,132.90 | -5.08 | -2.95 | -6.92 | -3.94 | 63.16 | 63.87 | -15.98 | -10.32 | 0.9844 | 56.43 | 0.2595 | -- | 51.94 | 3.12 | 74.69 | -- | 12.21 | -- |
| Mitie Group PLC | 4.62bn | 37.08m | 1.30bn | 72.00k | 37.21 | 2.60 | 10.94 | 0.2806 | 0.0208 | 0.034 | 2.69 | 0.2975 | 2.26 | 280.61 | 6.50 | 54,212.50 | 1.81 | 1.06 | 4.41 | 2.84 | 11.57 | 12.33 | 0.8019 | 0.5027 | 0.9279 | 10.28 | 0.4138 | 94.10 | 56.19 | 12.92 | 321.99 | -- | 5.76 | -2.68 |
| PostNL NV | 3.31bn | 132.00m | 1.33bn | 37.37k | 9.98 | 3.06 | 4.66 | 0.4028 | 0.2602 | 0.2698 | 6.56 | 0.8494 | 1.37 | 382.22 | 9.52 | 88,558.81 | 5.51 | 7.89 | 8.87 | 14.88 | 48.02 | 50.98 | 4.02 | 5.41 | 1.45 | 7.68 | 0.7018 | 60.12 | 6.48 | 0.3087 | 9.09 | -3.96 | 8.22 | 28.47 |
| YouGov Plc | 226.52m | 15.05m | 1.36bn | 1.21k | 92.82 | 9.98 | 32.44 | 6.01 | 0.112 | 0.112 | 1.69 | 1.04 | 0.9366 | -- | 5.02 | 157,625.70 | 6.17 | 6.15 | 8.91 | 8.68 | 85.09 | 82.89 | 6.59 | 7.04 | -- | 13.81 | 0.2294 | 44.31 | 10.86 | 13.89 | 20.32 | 27.59 | 31.37 | 33.78 |
Data as of Aug 09 2022. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
7.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 08 Jul 2022 | 371.93k | 2.01% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 237.56k | 1.28% |
| BlackRock Fund Advisorsas of 07 Jul 2022 | 183.66k | 0.99% |
| Santander Asset Management SA SGIICas of 30 Jun 2022 | 179.13k | 0.97% |
| Goldman Sachs Asset Management LPas of 28 Feb 2021 | 118.00k | 0.64% |
| Jupiter Asset Management Ltd.as of 30 Apr 2022 | 74.75k | 0.40% |
| BlackRock Advisors (UK) Ltd.as of 06 Jul 2022 | 71.17k | 0.38% |
| MainFirst Affiliated Fund Managers (Deutschland) GmbHas of 30 Jul 2021 | 58.44k | 0.32% |
| March Asset Management SGIIC SAUas of 31 Dec 2021 | 40.85k | 0.22% |
| SSgA Funds Management, Inc.as of 07 Jul 2022 | 39.43k | 0.21% |
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
